PL2524693T3 - Farmaceutyk do zapobiegania lub leczenia chorób, którym towarzyszy angiogeneza tkanki oka i/lub zwiększona przepuszczalność naczyń krwionośnych oka - Google Patents
Farmaceutyk do zapobiegania lub leczenia chorób, którym towarzyszy angiogeneza tkanki oka i/lub zwiększona przepuszczalność naczyń krwionośnych okaInfo
- Publication number
- PL2524693T3 PL2524693T3 PL11732936T PL11732936T PL2524693T3 PL 2524693 T3 PL2524693 T3 PL 2524693T3 PL 11732936 T PL11732936 T PL 11732936T PL 11732936 T PL11732936 T PL 11732936T PL 2524693 T3 PL2524693 T3 PL 2524693T3
- Authority
- PL
- Poland
- Prior art keywords
- ocular
- pharmaceutical
- preventing
- vascular permeability
- treating disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010006159 | 2010-01-14 | ||
JP2010055479 | 2010-03-12 | ||
PCT/JP2011/050472 WO2011087066A1 (ja) | 2010-01-14 | 2011-01-13 | 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
EP11732936.7A EP2524693B1 (en) | 2010-01-14 | 2011-01-13 | Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2524693T3 true PL2524693T3 (pl) | 2014-11-28 |
Family
ID=44304336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11732936T PL2524693T3 (pl) | 2010-01-14 | 2011-01-13 | Farmaceutyk do zapobiegania lub leczenia chorób, którym towarzyszy angiogeneza tkanki oka i/lub zwiększona przepuszczalność naczyń krwionośnych oka |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120301478A1 (pl) |
EP (1) | EP2524693B1 (pl) |
JP (2) | JP5212849B2 (pl) |
KR (1) | KR20120129904A (pl) |
CN (1) | CN102711756A (pl) |
AU (1) | AU2011206104A1 (pl) |
BR (1) | BR112012017071A2 (pl) |
CA (1) | CA2785970A1 (pl) |
DK (1) | DK2524693T3 (pl) |
ES (1) | ES2468827T3 (pl) |
MX (1) | MX2012007941A (pl) |
PL (1) | PL2524693T3 (pl) |
RU (1) | RU2012134639A (pl) |
WO (1) | WO2011087066A1 (pl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101482483B1 (ko) | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
AU2012101677B4 (en) * | 2012-07-03 | 2012-12-20 | Novartis Ag | Device |
US20160137717A1 (en) * | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
BR112018003741A2 (pt) | 2015-08-24 | 2018-09-25 | Glaxosmithkline Ip No 2 Ltd | composições biofarmacêuticas |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
MA53098A (fr) | 2018-02-02 | 2021-05-12 | Astellas Pharma Inc | Médicament pour prévenir ou traiter une maladie ophtalmique associée à une néovascularisation intraoculaire et/ou à une perméabilité vasculaire intraoculaire accrues |
JP2022502367A (ja) | 2018-09-24 | 2022-01-11 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61200991A (ja) | 1985-03-04 | 1986-09-05 | Sanwa Kagaku Kenkyusho:Kk | スピロ―3―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤 |
JP2997894B2 (ja) | 1990-11-07 | 2000-01-11 | 株式会社三和化学研究所 | 循環器系疾患の予防及び治療剤 |
JP3267698B2 (ja) | 1992-10-27 | 2002-03-18 | 株式会社三和化学研究所 | ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤 |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
JPH07242547A (ja) | 1994-03-02 | 1995-09-19 | Sanwa Kagaku Kenkyusho Co Ltd | 糖尿病性単純網膜症の進行阻止剤乃至治療剤 |
JP3603129B2 (ja) | 1994-12-28 | 2004-12-22 | 株式会社三和化学研究所 | 糖尿病性角膜症の治療剤 |
WO1999030157A2 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Neuropilins in methods for diagnosis and prognosis of cancer |
PL359027A1 (pl) | 2000-03-24 | 2004-08-23 | Novartis Ag | Udoskonalone leczenie neowaskularyzacji |
KR20030068205A (ko) | 2001-01-09 | 2003-08-19 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법 |
EP1381384B1 (en) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
IL161327A0 (en) * | 2001-11-09 | 2004-09-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
MXPA06003163A (es) | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
AU2004273619A1 (en) | 2003-09-23 | 2005-03-31 | Novartis Ag | Combinations of a VEGF receptor inhibitor with other therapeutic agents |
US7910615B2 (en) * | 2004-01-30 | 2011-03-22 | Sanwa Kagaku Kenkyusho Co., Ltd. | Prophylactic or therapeutic agent for diabetic maculopathy |
US20070299119A1 (en) * | 2004-02-20 | 2007-12-27 | Sanwa Kagaku Kenkyusho Co., Ltd. | Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy |
JP2008537538A (ja) | 2005-02-11 | 2008-09-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegf拮抗剤及び降圧剤の治療的組み合わせ |
EP1857107B1 (en) | 2005-02-22 | 2011-04-06 | Sanwa Kagaku Kenkyusho Co., Ltd | Preventive or therapeutic agent for cardiac dysfunction or myocardial damage caused by ischemia or ischemia-reperfusion |
ES2393271T3 (es) | 2005-12-16 | 2012-12-19 | Sanwa Kagaku Kenkyusho Co., Ltd | Agente para la prevención y tratamiento de la insuficiencia renal aguda |
JP2009525282A (ja) * | 2006-01-30 | 2009-07-09 | (オーエスアイ)アイテツク・インコーポレーテツド | 血管新生疾患の治療のための組み合わせ療法 |
CA2642933A1 (en) | 2006-02-20 | 2007-08-30 | Sanwa Kagaku Kenkyusho Co., Ltd. | Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke |
US20100111963A1 (en) * | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
JP5363123B2 (ja) | 2007-01-31 | 2013-12-11 | 株式会社三和化学研究所 | 網膜神経又は視神経の保護剤 |
US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
-
2011
- 2011-01-13 BR BR112012017071A patent/BR112012017071A2/pt not_active IP Right Cessation
- 2011-01-13 AU AU2011206104A patent/AU2011206104A1/en not_active Abandoned
- 2011-01-13 JP JP2011550006A patent/JP5212849B2/ja not_active Expired - Fee Related
- 2011-01-13 PL PL11732936T patent/PL2524693T3/pl unknown
- 2011-01-13 RU RU2012134639/15A patent/RU2012134639A/ru not_active Application Discontinuation
- 2011-01-13 CN CN2011800061758A patent/CN102711756A/zh active Pending
- 2011-01-13 KR KR1020127020695A patent/KR20120129904A/ko not_active Application Discontinuation
- 2011-01-13 WO PCT/JP2011/050472 patent/WO2011087066A1/ja active Application Filing
- 2011-01-13 ES ES11732936.7T patent/ES2468827T3/es active Active
- 2011-01-13 MX MX2012007941A patent/MX2012007941A/es active IP Right Grant
- 2011-01-13 DK DK11732936.7T patent/DK2524693T3/da active
- 2011-01-13 US US13/521,395 patent/US20120301478A1/en not_active Abandoned
- 2011-01-13 EP EP11732936.7A patent/EP2524693B1/en not_active Not-in-force
- 2011-01-13 CA CA2785970A patent/CA2785970A1/en not_active Abandoned
-
2012
- 2012-11-07 JP JP2012245734A patent/JP2013049701A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2524693B1 (en) | 2014-05-21 |
ES2468827T3 (es) | 2014-06-17 |
RU2012134639A (ru) | 2014-02-20 |
CN102711756A (zh) | 2012-10-03 |
BR112012017071A2 (pt) | 2016-04-12 |
JPWO2011087066A1 (ja) | 2013-05-20 |
CA2785970A1 (en) | 2011-07-21 |
EP2524693A4 (en) | 2013-05-22 |
JP5212849B2 (ja) | 2013-06-19 |
EP2524693A1 (en) | 2012-11-21 |
AU2011206104A1 (en) | 2012-07-12 |
MX2012007941A (es) | 2012-09-12 |
DK2524693T3 (da) | 2014-08-25 |
JP2013049701A (ja) | 2013-03-14 |
WO2011087066A1 (ja) | 2011-07-21 |
KR20120129904A (ko) | 2012-11-28 |
US20120301478A1 (en) | 2012-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2524693T3 (pl) | Farmaceutyk do zapobiegania lub leczenia chorób, którym towarzyszy angiogeneza tkanki oka i/lub zwiększona przepuszczalność naczyń krwionośnych oka | |
EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
IL225130A (en) | Devices for treating blood vessels defects | |
EP2432476A4 (en) | METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES | |
PT2740793T (pt) | Composição de fármacos para o tratamento e/ou a prevenção de cancro | |
EP2613735A4 (en) | DEVICES AND METHODS FOR THE TREATMENT OF VASCULAR ABNORMALITIES | |
HK1170490A1 (zh) | 用於青光眼的治療或預防的醫藥組合物 | |
IL253441A0 (en) | A medicine for the prevention and/or treatment of polycystic kidney disease | |
EP2825242A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DEFECTS | |
EP2671586A4 (en) | PHARMACOTHERAPY FOR THE PREVENTION OR TREATMENT OF GLAUCOMA | |
SI2838539T1 (sl) | Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj | |
PL2701645T3 (pl) | Urządzenie do leczenia i/lub zapobiegania chorobom rogówki | |
EP2938289A4 (en) | DEVICES AND METHODS FOR TREATING VASCULAR DEFECTS | |
HK1211960A1 (en) | Treating vascular disease and complications thereof | |
ZA201306613B (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
IL242355B (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
HK1207579A1 (en) | Composition for preventing or treating heart disease | |
IL229424A0 (en) | Pharmaceutical preparations containing neuropilin inhibitors and their uses in the prevention and/or treatment of angiogenic disorders and cancer | |
AP2011005843A0 (en) | Use of deferiprone for treatment and prevention ofiron-related eye disorders. | |
EP2830640A4 (en) | METHODS AND COMPOSITIONS FOR TREATING ARTERIOSCLEROSTIC VASCULAR DISEASES | |
EP2870971A4 (en) | MEDICAMENT FOR THE PREVENTION / TREATMENT OF AN OCULAR DISEASE | |
EP2826488A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS | |
EP2863930A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ARTERIOSCLEROSIS VASCULAR DISEASES | |
ZA201304121B (en) | Arlysulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders | |
ZA201406549B (en) | Methods and compositions for treating arteriosclerotic vascular diseases |